Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of long-chain non-coding RNA FAM83H-AS1 in the preparation of drugs for the treatment of non-small cell lung cancer

A technology of RNAFAM83H-AS1 and FAM83H-AS1, which can be used in DNA/RNA fragments, drug combinations, gene therapy, etc., can solve problems such as unmet medical needs, and achieve good clinical prospects, high inhibition efficiency, and good water solubility. Effect

Active Publication Date: 2019-02-15
JIANGSU CANCER HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The LNA platform provides a means to efficiently discover and develop an important class of new medicines that may address significant unmet medical needs across several therapeutic areas

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of long-chain non-coding RNA FAM83H-AS1 in the preparation of drugs for the treatment of non-small cell lung cancer
  • Application of long-chain non-coding RNA FAM83H-AS1 in the preparation of drugs for the treatment of non-small cell lung cancer
  • Application of long-chain non-coding RNA FAM83H-AS1 in the preparation of drugs for the treatment of non-small cell lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] The inventor provided normal lung tissue and lung cancer tissue samples, which were submitted to Boao Company for chip preparation. The human long-chain non-coding RNA chip V2.0 version completed the chip analysis. The chip contains the latest version of many LncRNAs databases, currently covering about tens of thousands. Probes for lncRNAs detection. The detection principle of the chip is based on the length and structural characteristics of the lncRNA sequence, using a combination of random primers and Oligo(dT) reverse transcription to introduce the T7 promoter, and then amplifying the RNA by linear amplification mediated by in vitro transcription. RNA linear amplification method for sample labeling in microarray chip analysis. The linear amplification product cRNA is reverse transcribed to obtain DNA, and then the DNA is fluorescently labeled with KlenowFragent enzyme, and finally the fluorescently labeled DNA product is hybridized with the Oligo probe on the chip fo...

Embodiment 2

[0081] Example 2 Detection of the expression of FAM83H-AS1 in tissues and cells

[0082] (1): The expression of FAM83H-AS1 in normal lung tissue and lung cancer tissue:

[0083] Chip preparation and analysis: Normal lung tissue and lung cancer tissue samples were prepared according to the requirements of Boao Company in China, and submitted to Bioau for chip preparation, and chip analysis was completed with the human long-chain non-coding RNA chip V2.0 version.

[0084] Chip results: The experimental data comes from Boao Company, and the results are shown in Figure 1.

[0085]Analysis of the results: FAM83H-AS1 was highly expressed in lung cancer tissue and low in normal lung tissue, with a difference of 18.79 times, suggesting that FAM83H-AS1 may function as an oncogene in lung cancer.

[0086] (2) qRT-PCR analysis of the expression profile of FAM83H-AS1 in normal lung tissue cell line 16-HBE and non-small cell lung cancer cell line

[0087] Methods: Trizol reagent was used...

Embodiment 2

[0090] Example 2. Design and construction of FAM83H-AS1-specific LNA transfected cells:

[0091] Design a specific interference sequence against FAM83H-AS1, its sequence is (5' to 3') see Seq NO.2, non-specific sequence (NC) is used as a control, and transfected into non-small cell lung cancer cell line A549 cells to play a role The effect of down-regulating the expression of FAM83H-AS1, and the transfection efficiency was detected after 48h.

[0092] Determination of results: as shown in Figure 3.

[0093] Analysis of the results: Compared with the control group, the cell proliferation ability of the LNA-FAM83H-AS1 group was significantly inhibited. This phenomenon was observed, suggesting that interfering with the expression of FAM83H-AS1 could inhibit the proliferation of non-small cell lung cancer cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of gene engineering, and particularly relates to application of long-chain non-coding RNA FAM83H-AS1 in preparation of medicine for treating non-small cell lung cancer. The expression of FAM83H-AS1 is changed through specific locked nucleic acid (LNA), and the expression of FAM83H-AS1 is lowered, so that non-small cell lung cancer cell proliferation, migration and invasion are inhibited, cell apoptosis is promoted, and then cell cycle is blocked. The long-chain non-coding RNA FAM83H-AS1 has the high inhibiting efficiency, is good in water solubility, can freely penetrate into cytomembrane, can be easily absorbed by the body, has no toxic effect in the body and has the good clinical prospect.

Description

technical field [0001] The invention relates to the application of long-chain non-coding RNA FAM83H-AS1 in the preparation of medicines for treating non-small cell lung cancer, and belongs to the field of genetic engineering. Background technique [0002] Cancer is one of the most common public health problems worldwide, and lung cancer is the leading cause of cancer-related death, accounting for 19.4% of all cancer deaths. In 2012, there were approximately 1.82 million new cases of lung cancer worldwide. The latest data from the National Cancer Registry Center shows that the incidence and mortality rate of lung cancer in my country has been ranking first among malignant tumors for many years, and the mortality rate has climbed to 37.00 / 100,000 people, seriously threatening the health of our people. It is estimated that by 2045, the number of deaths due to lung cancer in my country will be as high as 18 million. Lung cancer is divided into small cell lung cancer and non-sm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/113A61K48/00A61P35/00
CPCA61K48/00C12N15/113C12N2310/10C12N2310/3231
Inventor 尹荣许林邱满堂许有涛王洁董高超夏文佳陈瑞王思炜丁香香
Owner JIANGSU CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com